All articles tagged with #endocrinology
Doctors say the online cortisol scare is largely hype: cortisol is a normal, useful hormone with small, natural spikes; extreme claims and ads promising quick fixes lack solid evidence. Rare conditions like Cushing’s or Addison’s exist, but most people don’t have dangerous imbalances. Focus on stress management and consult a clinician rather than chasing supplements or TikTok guidance.
Experts rename polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its broader hormonal and metabolic features, not just ovarian cysts; diagnosis centers on irregular periods and signs of high androgens, with infertility and pregnancy risks acknowledged. Treatment emphasizes lifestyle changes and individualized options such as metformin, anti-androgens, and hormonal birth control based on fertility goals.
After a 14-year global consensus involving 56 organizations and about 22,000 participants, Polycystic Ovary Syndrome is officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its systemic hormonal and metabolic nature. The rename aims to reduce stigma, improve diagnosis, and align clinical practice over the next three years, with around 1 in 8 women affected by PMOS. The effort was led by researchers including Prof. Helena Teede and advocacy by Lorna Berry, highlighting the shift away from a cyst-centric view to a broader endocrine health perspective.
A global health consortium renames polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to better capture its multisystem nature, remove the misleading focus on ovaries, and reduce stigma. After 14 years of collaboration, the group plans to push PMOS into ICD classifications within three years and raise public and professional awareness. The condition affects about 170 million people worldwide, with up to 70% undiagnosed, and often involves metabolic, endocrine, psychological, and dermatological symptoms beyond reproduction. The renaming emphasizes insulin resistance and diabetes risk, potentially guiding research, screening, and treatment, including the continued, and sometimes off-label, use of drugs like metformin. The Lancet policy paper outlines the strategy to educate globally and secure official ICD updates.
Global experts publish in The Lancet a multiyear, multistakeholder process renaming polycystic ovary syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to avoid the cyst misnomer and better reflect its hormonal and metabolic features, with an eight‑stage plan—from dissemination and resource development to health‑system integration, policy alignment, and international guideline updates—aimed at clearer diagnosis and improved care.
Health researchers have renamed PCOS to PMOS (polyendocrine metabolic ovarian syndrome) to better reflect its wide hormonal and metabolic effects; a global consortium says the old name contributed to delayed diagnosis, stigma, and siloed research. The change could alter clinical care by prompting broader metabolic and cardiovascular screening, expand funding beyond reproductive health, and spur new treatments for the roughly 10–13% of reproductive-age women affected.
A Lancet-published renaming led by endocrinologist Helena Teede changes polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) to reflect the disorder’s wide metabolic and cardiovascular effects. Diagnosis shifts away from ovarian cysts, using 2 of 3 criteria (androgens, irregular menses, or high AMH/ovarian follicles), with ultrasound needing less emphasis. The rename is intended to broaden research funding and change treatment approaches beyond fertility, with PMOS slated to replace PCOS in ICD classification by 2028, though some opposition from those tied to the PCOS branding is expected.
After more than a decade of global consultation, polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its hormonal and metabolic impacts. Led by Prof. Helena Teede and backed by 56 medical and patient groups across six continents, the change aims to reduce misunderstanding and improve diagnosis and care, with the new name to be incorporated into international guidelines by 2028.
Live Science reports that polycystic ovary syndrome (PCOS) will be renamed polyendocrine metabolic ovarian syndrome (PMOS) to better reflect its hormonal and metabolic nature. The term “polycystic” is considered inaccurate since arrested follicles, not cysts, drive many features, and the name has contributed to confusion and stigma. The change was led by an international coalition of 56 organizations, with input from thousands of patients and clinicians, and is set to roll out over about three years. The acronym may continue as PMOS, and there are plans to update diagnostic language beyond ovaries to mirror the systemic endocrine-metabolic effects; this may also stimulate broader research and awareness beyond gynecology.
A global consensus study published in The Lancet renames polycystic ovary syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) to reflect its multisystem endocrine, metabolic, reproductive, dermatological and psychological effects. The change aims to update clinical guidelines, medical education, and international disease classifications, enabling earlier diagnosis, holistic patient-centered care, reduced fertility-related stigma, and expanded research into metabolic and systemic impacts.
Japanese researchers trained a modified ResNet-50 AI on more than 11,000 dorsal-hand and clenched-fist images from 716 patients across 15 facilities to diagnose acromegaly, achieving 89% sensitivity, 91% specificity, and an AUC of 0.96, outperforming 10 board-certified endocrinologists; the model employs privacy-by-design by excluding facial data, aiming for deployment in public health settings, though external validation and generalizability beyond Japanese patients remain to be shown.
Researchers trained a neural network on over 11,000 images of the back of the hand and clenched fists from 725 participants to diagnose acromegaly, achieving a positive predictive value of 0.88 and a negative predictive value of 0.93, and even outperforming endocrinology specialists in the same task. The approach offers privacy advantages over face-based methods and could speed screening, but it won’t replace clinicians; further validation in larger, diverse populations and exploration of other hand-related conditions are planned.
Kobe University researchers developed a privacy-first AI that detects acromegaly using only pictures of the back of the hand and a clenched fist, avoiding facial data. Trained on over 11,000 images from 725 patients across 15 centers in Japan, the model achieved high sensitivity and specificity and outperformed experienced endocrinologists, potentially speeding referrals and reducing healthcare disparities. The team plans to expand to other hand-visible conditions such as rheumatoid arthritis and anemia.
On World Thyroid Day 2024, Dr. Ashutosh Goyal shares natural ways to prevent thyroid diseases, including consuming a balanced diet rich in essential nutrients, maintaining good selenium levels, regular exercise, stress management, and ensuring quality sleep.
Endocrinologists in Utah are embracing a groundbreaking minimally invasive procedure for treating thyroid nodules, offering patients an alternative to major surgery. The innovative in-office procedure, recently approved by the FDA, has shown remarkable success in reducing nodule size and alleviating symptoms. Patients can now avoid invasive surgery and its associated scarring, recovery time, and lifelong reliance on hormone replacement medication. With coverage by a major Utah insurer and expected universal coverage in the coming months, this procedure marks a significant advancement in thyroid nodule treatment, providing newfound hope and relief for patients.